![Robert Postlethwaite](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert Postlethwaite
Career history of Robert Postlethwaite
Former positions of Robert Postlethwaite
Companies | Position | Start | End |
---|---|---|---|
AgeneBio, Inc.
![]() AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Director/Board Member | 2010-05-12 | - |
Cardinal Equity Partners LLC
![]() Cardinal Equity Partners LLC Investment ManagersFinance Cardinal Equity Partners LLC (Cardinal Equity Partners) is a private equity firm founded in 1993 by John F. Ackerman, James L. Smeltzer and Peter J. Munson. The firm is headquartered in Indianapolis, Indiana. | Private Equity Investor | 2009-11-25 | - |
Corporate Officer/Principal | 2007-12-31 | 2009-11-25 |
Statistics
International
United States | 3 |
Operational
Private Equity Investor | 1 |
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Sectoral
Finance | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Cardinal Equity Partners LLC
![]() Cardinal Equity Partners LLC Investment ManagersFinance Cardinal Equity Partners LLC (Cardinal Equity Partners) is a private equity firm founded in 1993 by John F. Ackerman, James L. Smeltzer and Peter J. Munson. The firm is headquartered in Indianapolis, Indiana. | Finance |
AgeneBio, Inc.
![]() AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
- Stock Market
- Insiders
- Robert Postlethwaite
- Experience